A potential target for Alzheimer's treatment? Researchers unearth new immune response pathway - Endpoints News

4/18/2022 12:00:00 AM3 yearsago
by Lei Lei Wu

Most Alzheimer’s drugs, including Biogen’s aducanumab (Aduhelm) and Eli Lilly’s donanemab, target amyloid plaques, misfolded protein clumps that build up in the brain, which are a hallmark of Alzheimer’s disease. However, researchers from Weill Cornell have u…

Most Alzheimer’s drugs, in­clud­ing Bio­gen’s ad­u­canum­ab (Aduhelm) and Eli Lil­ly’s do­nanemab, tar­get amy­loid plaques, mis­fold­ed pro­tein clumps that build up in the brain, which are a hall­m… [+2761 chars]

full article...